Health · Public Health & Disease · 4 hrs ago
Up to 2.5 million people in Mexico have psoriasis, but few get biologics
Up to 2.5 million people in Mexico have psoriasis, a chronic disease linked to the immune system that causes inflamed, scaly skin.
Only 14% receive biologic therapies, which target parts of the inflammation process and are among the newer treatment options.
Around 25% to 30% of patients in Mexico have moderate to severe psoriasis, and many struggle to control it with conventional treatments.
Barriers include late assessment and limited access to newer therapies, as well as continuing treatments that are not working well enough.
Poorly controlled psoriasis can affect more than the skin, harming sleep, mental health and relationships, and raising the risk of other conditions such as psoriatic arthritis.
Doctors say treatment goals should be set clearly and a patient's response checked after a few months, so therapy can be adjusted if needed.
Up to 2.5 million people in Mexico have psoriasis, but only 14% of patients receive biologic therapy, according to information presented by Johnson & Johnson.
Between 25% and 30% of patients in Mexico have moderate to severe forms of the disease.
Reported barriers to adequate control include late assessment of severity, continued use of treatments that do not work well enough and difficulty accessing newer therapies.
Psoriasis can affect quality of life beyond the skin and is associated with conditions including psoriatic arthritis and a higher risk of cardiovascular disease.
- Who
- Up to 2.5 million people in Mexico have psoriasis. Only 14% of patients receive biologic therapy.
- What
- Access to biologic treatments for psoriasis remains limited.
- When
- The information was presented for World Psoriasis Day, observed on October 29. The article was published on October 29, 2026.
- Where
- Mexico.
- Why
- The sources cite barriers including late assessment of disease severity, continued use of ineffective treatments and difficulty accessing newer options.
This story does not have two clearly opposing sides.
Psoriasis treatment has shifted from topical medicines, phototherapy and conventional systemic therapies toward biologic medicines.
World Psoriasis Day is observed, and Johnson & Johnson presented information on psoriasis and treatment access in Mexico.
- People affected in Mexico
- Up to 2.5 million
- Patients receiving biologics
- 14%
- Moderate to severe cases in Mexico
- 25% to 30%
- World Psoriasis Day
- October 29
- Publication date
- October 29, 2026
1 source
What people are saying
Despite the important advances made in recent years with the arrival of biologic therapies, we can clearly see that unmet needs remain and that patients and health systems face a major impact on quality of life.
Moderate to severe psoriasis is measured not only by how much skin is affected, but by how much it takes away from a patient's life.